Patent
No: US 6,143,327
Expiry
Date: 30 October 2018
Owner: Pharm Pass LLC
Licensed to
Biovail Corporation
Sublicensed
to GlaxoSmithKline
Type
of Patent: Drug Product
The
undersigned declares the above United States Patents cover the composition of
Wellbutrin XL tablets. This product is
the subject of this application for which approval is being sought.
Please
address all communications to:
Robert
H. Brink
VP
– Pharmaceuticals Patents – RTP
Five
Moore Drive
PO
Box 13398
RTP,
North Carolina 2709-3398
(signed
and dated July 18, 2002) _____/S/_____________
Robert
H. Brink
Registration
No. 36,094
Stamped:
APPEARS THIS WAY ON ORIGINAL
Back a Page
Next Page
Back to Wellbutrin XL NDA Index Page
Back to Main Index Page